Field Trip Health Ltd. to Present at the Cowen Psychedelics & Novel Mechanisms in Neuropsychiatry Summit

Rhea-AI Summary

Field Trip Health Ltd. announces participation in the Cowen Psychedelics & Novel Mechanisms in Neuropsychiatry Summit on July 13, 2021. Ronan Levy, Co-Founder & Executive Chairman, will engage in a panel discussion titled “Emerging Psychedelic Therapies In The Field Of Neuropsych” at 4:15 PM EST. The company is a leader in developing psychedelic therapies, with a significant focus on innovative treatments and research.

For investor meetings, please reach out to Cowen representatives for scheduling.

TORONTO, July 08, 2021 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP; FTRP.WT; OTCQX: FTRPF) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that Ronan Levy, Co-Founder & Executive Chairman, will take part in a panel discussion and participate in one-on-one investor meetings at the Cowen Psychedelics & Novel Mechanisms in Neuropsychiatry Summit on July 13, 2021.

The panel discussion, entitled “Emerging Psychedelic Therapies In The Field Of Neuropsych” will take place on Tuesday, July 13, 2021, at 4:15 PM EST.

Investors that are interested in scheduling a meeting should contact their Cowen representative for more information.

About Field Trip Health Ltd.

Field Trip is a global leader in the development and delivery of psychedelic therapies. With our Field Trip Discovery division leading the development of the next generation of psychedelic molecules and conducting advanced research on plant-based psychedelics and our Field Trip Health division building centers for psychedelic therapies opening across North America and Europe along with the digital and technological tools that will enable massive scale, we help people in need with a simple, evidence-based way to heal and heighten engagement with the world.

Learn more at https://www.meetfieldtrip.com, https://www.fieldtriphealth.com and https://www.fieldtriphealth.nl.

Follow us on Twitter and Instagram: @fieldtriphealth

To receive company updates about Field Trip and to be added to the email distribution list please sign up here.

For further information, contact Ronan Levy, Executive Chairman and a Director at Field Trip, at 1 (833) 833-1967.

Cautionary Note Regarding Forward-Looking Information.

This release includes forward-looking information within the meaning of Canadian securities laws regarding Field Trip and its business. Often but not always, forward-looking information can be identified by the use of words such as "expect", "intends", "anticipated", "believes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would" or "will" be taken, occur or be achieved. Such statements are based on the current expectations and views of future events of the management of Field Trip, and are based on assumptions and subject to risks and uncertainties. Although the management of Field Trip believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the companies, including risks regarding listing of our common shares on NASDAQ, the timing and results of its research and development programs, approval of phase 1 human trials, if any, the risk that future clinical studies may not proceed as expected or may produce unfavorable results, the opening of additional clinics, the COVID-19 epidemic, the medical clinic industry, market conditions, economic factors, management's ability to manage and to operate the business and the equity markets generally. Although Field Trip has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Field Trip does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

Neither the Toronto Stock Exchange, nor its Regulation Services Provider, nor the OTC Markets have approved the contents of this release or accept responsibility for the adequacy or accuracy of this release.

Media contacts:
Rachel Moskowitz
Autumn Communications
202-276-7881
press@fieldtriphealth.com

Nick Opich / McKenna Miller
KCSA Strategic Communications
212-896-1206 / 347-487-6197
press@fieldtriphealth.com

Investor contacts:
Elizabeth Barker
KCSA Strategic Communications
212-896-1203
ebarker@kcsa.com

SOURCE Field Trip Health Ltd.

FAQ

What is the date and time of Field Trip Health's panel discussion at the Cowen Summit?

Field Trip Health's panel discussion is scheduled for July 13, 2021, at 4:15 PM EST.

Who is representing Field Trip Health at the Cowen Summit?

Ronan Levy, Co-Founder & Executive Chairman, will represent Field Trip Health at the Cowen Summit.

What is the focus of the Cowen Psychedelics Summit where Field Trip is participating?

The Cowen Psychedelics Summit focuses on emerging psychedelic therapies in the field of neuropsych.

How can investors schedule a meeting with Field Trip Health during the Cowen Summit?

Investors interested in meetings should contact their Cowen representative for more information.

What is Field Trip Health's approach to psychedelic therapies?

Field Trip Health focuses on developing evidence-based psychedelic therapies and building supportive centers across North America and Europe.